Lineage Cell Therapeutics Logo
US53566P1093
A2PP89
LCTX.TA

Lineage Cell Therapeutics

Prévisions

Acheter
  5
Conserver
  0
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028

    Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » Plus sur finance.yahoo.com


  • Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028

    Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » Plus sur de.investing.com


  • Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million

    Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » Plus sur de.investing.com


  • Lineage Cell Therapeutics withdraws CIRM grant application and plans resubmission

    Lineage Cell Therapeutics withdrew its CLIN2 grant application to the California Institute for Regenerative Medicine after receiving feedback and plans to submit a revised application in the next CIRM cycle in January 2026. CIRM did not identify any specific substantive deficiencies, and the company will continue development activities for OPC1 unchanged. The ongoing DOSED study for OPC1 administration is proceeding as planned. Lineage also reported Q3 results with EPS of -$0.13 (below expectations) and revenue of $3.68 million (above expectations), raised $21 million through an ATM sale, and reported its stock price and market capitalization. » Plus sur de.investing.com


  • Lineage reaches 52-week low at $32.78

    Lineage stock fell to a 52-week low of $32.78 and is currently trading near that level, well below its high of $66.38. Year-to-date the price is down about 41.04%, and it fell 48.21% last year. InvestingPro rates the stock as fairly valued, with analyst price targets ranging from $38 to $70. For Q3 Lineage reported record revenue of $1.37 billion but posted a loss per share and cut its full-year forecast; several banks have lowered price targets or adjusted ratings. Despite the loss, Lineage offers a dividend yield of 6.32%, providing investors with short-term income at increased risk. » Plus sur de.investing.com

En 2003, Lineage Cell Therapeutics a déjà versé 0,0651 € de dividendes. Le dernier versement a eu lieu en décembre 2003.

Données financières

Au dernier trimestre, Lineage Cell Therapeutics a réalisé un chiffre d'affaires de 1,27 M € et un bénéfice net de 3,74 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 1,27 M 59,64 %
Bénéfice brut 1,26 M 59,72 %
Bénéfice net 3,74 M 114,72 %
EBITDA 4,34 M 117,22 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
177,95 M €
Nombre d'actions
252,95 M
Plus haut/bas sur 52 semaines
1,81 € - 0,70 €
Dividendes Non
Bêta
1,69
Ratio P/E
-25,56
Ratio PEG
-0,15
Ratio P/B
2,91
Ratio P/S
18,02

Profil de l'entreprise

Lineage Cell Therapeutics, Inc., une société de biotechnologie au stade clinique, développe de nouvelles thérapies cellulaires pour le traitement des maladies dégénératives aux États-Unis et à l'international. La société développe OpRegen, une thérapie de remplacement de cellules de l'épithélium pigmentaire rétinien, actuellement en essai clinique de phase I/IIa pour le traitement de la dégénérescence maculaire liée à l'âge sèche ; OPC1, une thérapie à base de cellules progénitrices d'oligodendrocytes, en essai clinique multicentrique de phase I/IIa pour le traitement des lésions aiguës de la moelle épinière ; et VAC2, une immunothérapie anticancéreuse allogénique à base de cellules dendritiques présentatrices d'antigènes, en essai clinique de phase I pour le traitement du cancer du poumon non à petites cellules. Elle propose également Renevia, un produit d'esthétique faciale. En outre, la société mène des activités de recherche et développement de produits thérapeutiques pour les maladies rétiniennes, les maladies neurologiques, ainsi que pour les troubles et l'oncologie. Lineage Cell Therapeutics, Inc. a conclu une collaboration avec Orbit Biomedical, Ltd. La société était auparavant connue sous le nom de BioTime, Inc. et a changé de nom pour devenir Lineage Cell Therapeutics, Inc. en août 2019. Lineage Cell Therapeutics, Inc. a été constituée en 1990 et son siège social se trouve à Carlsbad, en Californie.

Nom
Lineage Cell Therapeutics
PDG
Brian Culley
Siège social Carlsbad, ca
États-Unis
Site web
Secteur
Consommation de base
Industrie
Produits alimentaires
Introduction en bourse
05/03/1992
Employés 75

Symboles boursiers

Bourse Symbole
Tlv
LCTX.TA
AMEX
LCTX
Frankfurt
BT3.F
Düsseldorf
BT3.DU
🍪

Parqet  utilise des cookies. En savoir plus